Bora Pharmaceuticals Co (保瑞藥業) is still looking at contract development and manufacturing organizations (CDMOs) as potential merger and acquisition (M&A) targets, as the company continues to expand its business scale, the medicine and healthcare product maker said yesterday.
The company has seen its market value surge by more than 50-fold in seven years through a series of strategic M&As, including acquiring Japan-based Eisai Co’s subsidiary and plant in Tainan’s Guantian District (官田) in 2013 and US-based Impax Laboratories Inc’s subsidiary and plant in Miaoli County’s Jhunan Township (竹南) in 2018.
“We expect to see new M&A opportunities emerge next year,” Chinese-language online news outlet Cnyes.com quoted Bora Pharmaceuticals chairman Bobby Sheng (盛保熙) as saying. “There are not many buyers in the US M&A market and the valuations of many CDMOs are much cheaper than before, which is relatively beneficial to us.”
Photo: CNA
Sheng made the remarks at a ceremony at the Taiwan Stock Exchange (TWSE), where the company made its share debut on the main board after transferring its listing from the Taipei Exchange.
Bora Pharmaceuticals shares fell 3.1 percent to close at NT$657, in line with losses across the main exchange. Prior to yesterday, the stock had surged more than 60 percent since the beginning of this year.
Due to the growing market demand for drugs, several major clients have already discussed placing more orders, Bora Pharmaceuticals said.
As a result, the company has furthered its acquisition efforts, including factories, companies and product portfolios, it said.
It would also continue to adjust product strategy at its subsidiary TWi Pharmaceuticals Inc (安成藥) in a bid to diversify away from generic drugs, after the unit in August acquired six brand product licenses and technologies from Morristown, New Jersey-based Almatica Pharma Inc, it said.
The new strategy would enable Bora to leverage its sales platforms to enter the brand product market, create a new revenue driver and improve its profit margin, as well as allow the company to have more resources for future investment, it said.
Bora Pharmaceuticals’ consolidated revenue grew 50.25 percent year-on-year to NT$13.25 billion (US$422.5 million) in the first 11 months of this year, ranking second among Taiwanese pharmaceutical companies, TWSE data showed.
Net profit in the first three quarters totaled NT$2.47 billion, up 149.43 percent from the same period last year, with earnings per share rising from NT$10.12 to NT$24.63 and gross margin improving from 35.02 percent to 48.16 percent, the data showed.
SETBACK: Apple’s India iPhone push has been disrupted after Foxconn recalled hundreds of Chinese engineers, amid Beijing’s attempts to curb tech transfers Apple Inc assembly partner Hon Hai Precision Industry Co (鴻海精密), also known internationally as Foxconn Technology Group (富士康科技集團), has recalled about 300 Chinese engineers from a factory in India, the latest setback for the iPhone maker’s push to rapidly expand in the country. The extraction of Chinese workers from the factory of Yuzhan Technology (India) Private Ltd, a Hon Hai component unit, in southern Tamil Nadu state, is the second such move in a few months. The company has started flying in Taiwanese engineers to replace staff leaving, people familiar with the matter said, asking not to be named, as the
The prices of gasoline and diesel at domestic fuel stations are to rise NT$0.1 and NT$0.4 per liter this week respectively, after international crude oil prices rose last week, CPC Corp, Taiwan (台灣中油) and Formosa Petrochemical Corp (台塑石化) announced yesterday. Effective today, gasoline prices at CPC and Formosa stations are to rise to NT$27.3, NT$28.8 and NT$30.8 per liter for 92, 95 and 98-octane unleaded gasoline respectively, the companies said in separate statements. The price of premium diesel is to rise to NT$26.2 per liter at CPC stations and NT$26 at Formosa pumps, they said. The announcements came after international crude oil prices
SinoPac Financial Holdings Co (永豐金控) is weighing whether to add a life insurance business to its portfolio, but would tread cautiously after completing three acquisitions in quick succession, president Stanley Chu (朱士廷) said yesterday. “We are carefully considering whether life insurance should play a role in SinoPac’s business map,” Chu told reporters ahead of an earnings conference. “Our priority is to ensure the success of the deals we have already made, even though we are tracking some possible targets.” Local media have reported that Mercuries Life Insurance Co (三商美邦人壽), which is seeking buyers amid financial strains, has invited three financial
CAUTION: Right now, artificial intelligence runs on faith, not productivity and eventually, the risk of a bubble will emerge,’ TIER economist Gordon Sun said Taiwanese manufacturers turned more optimistic last month, ending a five-month streak of declining sentiment as concerns over US tariffs, currency volatility and China’s overcapacity began to ease, the Taiwan Institute of Economic Research (TIER) said yesterday. The manufacturing business confidence index rose 1.17 points from June to 86.8, its first rebound since February. TIER economist Gordon Sun (孫明德) attributed the uptick to fading trade uncertainties, a steadier New Taiwan dollar and reduced competitive pressure from Chinese producers. Taiwan’s semiconductor industry is unlikely to face significant damage from Washington’s ongoing probe into semiconductors, given the US’ reliance on Taiwanese chips to power artificial
RSS